HC Wainwright Reiterates Buy Rating on Adagene, Keeps $7 Price Target
HC Wainwright reiterated its Buy rating on Adagene and maintained a $7 price target. The target implies 239.8% upside from the October 16 close of $2.06.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.